Clinical Trials (Gastrointestinal)

Research studies conducted with cancer patients are called clinical trials. As a cancer patient, you may take part in a clinical trial. Please see the links below for current open trials at UC San Francisco. 

CC#187015: A Phase 2 Study of Perioperative Immunotherapy in Patients with Colorectal Cancer and Resectable Hepatic Metastases
Contact: Marissa Gin (415) 476-3816: [email protected]
 
Colorectal Non-Therapeutic Studies
 
CC#134510: GIMP: Molecular Profiling in Gastrointestinal Malignancies
Contact: Dalila Stanfield (415) 476-2976: [email protected]
 
CC#154520: Lifestyle and Outcomes after Gastrointestinal Cancer: A Prospective Cohort Study (LOGIC)
Contact: Dalila Stanfield (415) 476-2976: [email protected]      
 
CC#174527: GO – Gut Microbiome and Oral Fluoropyrimidine Study in Patients with Colorectal Cancer
Contact: Dalila Stanfield (415) 476-2976: [email protected]
 
CC#19801: Digital Symptom Tracking, Patient Engagement and Quality of Life in Advanced Cancer
Contact: Ashna Sethi (415) 353-1745: [email protected]
 
CC#204518: BESPOKE Study of ctDNA-Guided Therapy in Colorectal Cancer
Contact: Marin Pollak (415) 476-7974: [email protected]
 
CC#21456: Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Colorectal Cancer Survivors (Tools To Be Fit)
Contact: Quincy Harris (415) 353-9544: [email protected]
https://toolstobefit.eurekaplatform.org/
 
CC#214519: Evaluation of a Pilot Integrated Rectal Cancer Exercise Program (REP’s)
Contact: Banaz Shwan (415) 514-7285: [email protected]
 
CC#21981: Understanding barriers to uptake of integrative oncology among Black patients with cancer
Contact: Dalila Stanfield (415) 476-2976: [email protected]

AMC095: A Phase 1 Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors
Contact: Yuwen Jian [email protected]
  
CC#19958: First-In-Human, Open-Label, Phase I Dose Escalation and Cohort Expansion Study of BB-1701 in Locally Advanced/Metastatic Her2 Expressing Solid Tumors
Contact: Kristy Tjokro: [email protected]  
 
CC#18956: A Phase 1B Dose Escalation/Expansion Study of Abexinostat in Combination with Pembrolizumab in Patients with Advanced Solid Tumor Malignancies
Contact: Nela Pawlowska: [email protected]  
 
CC#189510: A Phase II Trial of AZD6738 Alone and in Combination with Olaparib in Patients with Selected Solid Tumor Malignancies
Contact: Yuwen Jian [email protected]
  
CC#189513: A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and IN combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma
Contact: Michelle Howell [email protected]
 
CC#189514: A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants with Relapsed/Refractory Solid Tumors RMC-4630 is a potent, selective, and orally bioavailable SHP2 allosteric inhibitor that is being developed for patients with tumors harboring certain activating mutations or other genotypic aberrations in the RAS–MAPK pathway, including upstream mutations in RTKs.
Contact: Maria Mir: [email protected]
 
CC#19954: A Phase 1 Multicenter, Open-Label, Dose-Escalation an Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of AO_176
Contact: Maria Mir: [email protected]
 
CC#19955: Protocol 101-18101 – An Open Label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors
Contact: Anna Nguyen: [email protected]       
 
CC#19956: Protocol RMC 4360 02: A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 in combination with Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors
Contact: Maria Mir: [email protected]
 
CC#199511: A Phase 1/2 Study of CYT-0851 (a RAD51 inhibitor) in Patients with Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Contact: Anna Nguyen: [email protected] 
 
CC#199516: Phase 1/1b Study of TPST-1120 () as Single Agent or w/Systemic Anti-Cancer Therapies in Patients with Advanced Solid Tumors
Contact: Nela Pawlowksa: [email protected]
 
CC#209511: A first in human study of highly selective FGFR2 inhibitor, RLY-4008 in patients with intrahepatic cholangiocarcinoma (ICC)
Contact: Nela Pawlowska: [email protected]
 
CC#209517: A Phase 1/2 Trial of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation
Contact: Phu Lam: [email protected]
                                                                                                                                                           
CC#20958: A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination with Dabrafenib for the treatment of Advanced Solid Tumors with MAPK Pathway Mutations
Contact: Nela Pawlowksa: [email protected]
Not currently enrolling
 
CC#20959: A Phase 1/2 Open Label, Dose Escalation, and Cohort Expansion of Clinical Trial of ARV-471 Alone and in Combination with Palbociclib (IBRANCE) in Patients with ER+/HER- Locally Advanced or Metastatic Breast Cancer
Contact: Kristy Tjokro: [email protected]  
 
CC#209515: A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)                                                                                                                          
Contact: Kristy Tjokro: [email protected]
 
CC#209516: Phase II Trial of Targeted Therapies or Immunotherapy as a Single Agent or in Rational in Patients with Advanced Solid Tumors Harboring Specific Mutations or who are TMB-High
Contact: Nela Pawlowska: [email protected]
 
CC#209518: A Phase 1, Open-label, Multi-Center, Dose-Finding, Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 in Participants with Selected Advanced or Metastatic Solid Tumor Malignancies
Contact: Phu Lam: [email protected]
 
CC#21951: LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-Randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients with an Advanced Solid Tumor 
Contact: Yuwen Jian: [email protected]

CC#21704: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies
Contact: Marissa Gin (415) 476-3816: [email protected]
 

CC#197010: A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients with Advanced Mesothelin-Expressing Cancer
Contact: Carolyn Bridgman (415) 514-7975: [email protected]sf.edu
 
CC#174523: Multicenter Pilot Study of the Safety, Efficacy, and Immune Cell
Profiling in Advanced Hepatocellular Carcinoma (HCC) Patients Treated with the Combination of Sorafenib plus Nivolumab as First-Line of Systemic Therapy
Contact: Lauren Ford (415) 353-7284: [email protected]
 
CC# 204521: LOXO-IDH-20002 A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 Mutations
Contact: Ashna Sethi (415) 353-1745: [email protected]
 
CC#204517: A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Advanced Liver Cancers (Morpheus-Liver)
Contact: Ashna Sethi (415) 353-1745: [email protected]
 
CC#207021: A Phase 1 Study of SRF388 in Patients with Advanced Solid Tumors
Contact: Chris De Leon (415) 476-2958: [email protected]
Not currently enrolling for GI indications
 
CC#194522: Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients with Metastatic Gastrointestinal Malignancies Progressing on Immune Therapy (ARM-GI)
Contact: Luchia Andemicael (415) 476-8099: [email protected]
 
Hepatocellular and Biliary Tract Non-Therapeutic Studies
 
CC#124512: Banking of Human Biological Specimens for Hepatobiliary Cancer Research Studies: UCSF Hepatobiliary Tissue Bank and Registry
Contact: Karen Zhang (415) 502-1877: [email protected]
 
CC#174535: A 5-year Longitudinal Observational Study of the Natural History and Management of Patients With Hepatocellular Carcinoma (HCC)
Contact: Karen Zhang (415) 502-1877: [email protected]
 
CC#204516: A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)
Contact: Karen Zhang (415) 502-1877: [email protected]

CC#17705: A Pilot Study of Pembrolizumab and Liver Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases.
Contact: Chris De Leon (415) 476-2958: [email protected]
 
CC#187011: A Phase 1/1b Multicenter Study to Evaluate the Humanized Anti-CD73 Antibody, CPI-006, as a Single Agent or in Combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant Plus Pembrolizumab in Adult Subjects with Advanced Cancers
Contact: Saba Saidi (415) 353-8202: [email protected]
Not currently enrolling
 
CC#197010: A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer
Contact: Carolyn Bridgman (415) 514-7975: [email protected]
 
CC#207021: A Phase 1 Study of SRF388 in Patients with Advanced Solid Tumors
Contact: Chris De Leon (415) 476-2958: [email protected]
Not currently enrolling for GI indications
 
CC#187015: A Phase 2 Study of Perioperative Immunotherapy in Patients with Colorectal Cancer and Resectable Hepatic Metastases
Contact: Marissa Gin (415) 476-3816: [email protected]
 
CC#21704: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies
Contact: Marissa Gin (415) 476-3816: [email protected]
 
CC#21708: A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors
Contact: Saba Saidi (415) 353-8202: [email protected]

CC#17705: A Pilot Study of Pembrolizumab and Liver-Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases
Contact: Chris De Leon (415) 476-2958: [email protected]
 
A021602: Randomized, Double-Blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus (CABINET)
Contact: Bryan Le (415) 502-6313: [email protected]
 
Neuroendocrine Tumors Non-Therapeutic Studies
 
CC#194520: e-NET: A Pilot Study Using a Web-Based Health Platform to Investigate Health-Related Quality of Life in Patients with Neuroendocrine Tumors
Contact: Farhana Moon: [email protected], [email protected]
https://enet.eurekaplatform.org/
 

Therapeutic trials actively recruiting

Pancreatic ductal adenocarcinoma

Pancreatic neuroendocrine tumors

Non-Therapeutic trials

 
A021901: Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors
Contact: Faaiz Ibrahim (415) 514-8101: [email protected]
 
CC# 214515: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Multiple Solid Tumors
Contact: Kelly Bauer (415) 514-5633: [email protected]
 
CC#214514: A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3)
Contact: Faaiz Ibrahim (415) 514-8101: [email protected]
 
CC#21709: An Open Label Phase 1A/B Study of MTL-CEBPA in Combination with a PD-1 Inhibitor (PEMBROLIZUMAB) in Adult Patients with Advanced Solid Tumors (TIMEPOINT)
Contact: Carolyn Bridgman (415) 514-7975: [email protected]
 
CC#22454: A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination with Hydroxychloroquine in Patients with Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations (BVD-523-HCQ)
Contact: Alex Milloy (415) 502-3310: [email protected]